These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1616832)

  • 1. Good outcome in anti-glomerular basement membrane nephritis.
    Gilvarry J; Doyle GF; Gill DG
    Pediatr Nephrol; 1992 May; 6(3):244-6. PubMed ID: 1616832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Goodpasture's syndrome with immunosuppression and plasmapheresis.
    Finch RA; Rutsky EA; McGowan E; Wilson CB
    South Med J; 1979 Oct; 72(10):1288-90. PubMed ID: 482987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Goodpasture's syndrome: treatment with plasmapheresis, immunosuppression, and anticoagulation.
    Levin M; Rigden SP; Pincott JR; Lockwood CM; Barratt TM; Dillon MJ
    Arch Dis Child; 1983 Sep; 58(9):697-702. PubMed ID: 6625631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplantation, immunosuppression and plasmapheresis in Goodpasture's syndrome.
    Cove-Smith JR; McLeod AA; Blamey RW; Knapp MS; Reeves WG; Wilson CB
    Clin Nephrol; 1978 Mar; 9(3):126-8. PubMed ID: 346273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of plasma exchange and immunosuppression to improve renal function in Goodpasture's syndrome.
    McLeish KR; Maxwell DR; Luft FC
    Clin Nephrol; 1978 Aug; 10(2):71-3. PubMed ID: 699402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Goodpasture's syndrome in a child: natural history and effect of treatment.
    Martini A; Binda S; Mariani G; Scotta MS; Ruberto G
    Acta Paediatr Scand; 1981; 70(3):435-9. PubMed ID: 7246141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goodpasture's syndrome with absence of circulating anti-glomerular basement membrane antibodies: a case report.
    Fernandes R; Freitas S; Cunha P; Alves G; Cotter J
    J Med Case Rep; 2016 Jul; 10():205. PubMed ID: 27459964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Goodpasture's syndrome: recurrence after a five-year remission. Case report and review of the literature.
    Klasa RJ; Abboud RT; Ballon HS; Grossman L
    Am J Med; 1988 Apr; 84(4):751-5. PubMed ID: 3041810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spectrum of renal diseases associated with anti-basement membrane antibodies.
    Senekjian HO; Knight TF; Weinman EJ
    Arch Intern Med; 1980 Jan; 140(1):79-81. PubMed ID: 6986125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Goodpasture's syndrome with plasmapheresis. A case report and review of the literature.
    Rosenblatt SG; Knight W; Bannayan GA; Wilson CB; Stein JH
    Am J Med; 1979 Apr; 66(4):689-96. PubMed ID: 433973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Goodpasture's syndrome--effects of plasmapheresis.
    Munk ZM; Skamene E
    Clin Exp Immunol; 1979 May; 36(2):244-9. PubMed ID: 477027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis.
    Lockwood CM; Boulton-Jones JM; Lowenthal RM; Simpson IJ; Peters DK
    Br Med J; 1975 May; 2(5965):252-4. PubMed ID: 1131574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis/Goodpasture's syndrome.
    Walker RG; Scheinkestel C; Becker GJ; Owen JE; Dowling JP; Kincaid-Smith P
    Q J Med; 1985 Jan; 54(213):75-89. PubMed ID: 3975346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture's syndrome.
    Erickson SB; Kurtz SB; Donadio JV; Holley KE; Wilson CB; Pineda AA
    Mayo Clin Proc; 1979 Nov; 54(11):714-20. PubMed ID: 491763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease.
    Reynolds J; Moss J; Duda MA; Smith J; Karkar AM; Macherla V; Shore I; Evans DJ; Woodrow DF; Pusey CD
    J Pathol; 2003 May; 200(1):118-29. PubMed ID: 12692850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penicillamine-induced "Goodpasture's syndrome": successful treatment of a fulminant case.
    Gavaghan TE; McNaught PJ; Ralston M; Hayes JM
    Aust N Z J Med; 1981 Jun; 11(3):261-5. PubMed ID: 6945838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights on Goodpasture's syndrome.
    Wiseman KC
    ANNA J; 1993 Feb; 20(1):17-26. PubMed ID: 8431025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture's syndrome.
    Johnson JP; Whitman W; Briggs WA; Wilson CB
    Am J Med; 1978 Feb; 64(2):354-9. PubMed ID: 629280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Plasmapheresis in a Patient with Anti-glomerular Basement Membrane Antibody Glomerulonephritis with Advanced Kidney Dysfunction.
    Usui T; Kai H; Noguchi K; Morito N; Usui J; Saito C; Uesugi N; Nagata M; Yamagata K
    Intern Med; 2017 Sep; 56(18):2475-2479. PubMed ID: 28824070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atypical form of Goodpasture's disease].
    Habánová M; Divácká P; Řehořová J; Svobodová I
    Vnitr Lek; 2023; 69(5):316-321. PubMed ID: 37827830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.